[1]王明杰,秦玉杰.聚乙二醇干扰素α序贯联合核苷类药物治疗高病毒载量e抗原阳性乙型肝炎的疗效[J].医学信息,2021,34(19):107-109.[doi:10.3969/j.issn.1006-1959.2021.19.027]
　WANG Ming-jie,QIN Yu-jie.Efficacy of Peginterferon α Sequential Combined with Nucleoside Drugs in theTreatment of High Viral Load e Antigen Positive Hepatitis B[J].Medical Information,2021,34(19):107-109.[doi:10.3969/j.issn.1006-1959.2021.19.027]
点击复制

聚乙二醇干扰素α序贯联合核苷类药物治疗高病毒载量e抗原阳性乙型肝炎的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年19期
页码:
107-109
栏目:
论著
出版日期:
2021-10-01

文章信息/Info

Title:
Efficacy of Peginterferon α Sequential Combined with Nucleoside Drugs in theTreatment of High Viral Load e Antigen Positive Hepatitis B
文章编号:
1006-1959（2021）19-0107-03
作者:
王明杰; 秦玉杰
天津市滨海新区海滨人民医院感染性疾病科，天津 300280
Author(s):
WANG Ming-jie; QIN Yu-jie
Department of Infectious Diseases,Tianjin Binhai New Area People’s Hospital,Tianjin 300280,China
关键词:
聚乙二醇干扰素α; 核苷类药物; 乙型肝炎; 高病毒载量; e抗原阳性
Keywords:
Peginterferon α; Nucleoside drugs; Hepatitis B; High viral load; e antigen positive
分类号:
R512.62
DOI:
10.3969/j.issn.1006-1959.2021.19.027
文献标志码:
A
摘要:
目的 研究聚乙二醇干扰素α序贯联合核苷类药物治疗高病毒载量e抗原阳性乙型肝炎的临床疗效。方法 选取2019年8月-2020年4月我院诊治的68例高病毒载量e抗原阳性乙型肝炎患者为研究对象，采用随机数字表法分为对照组和观察组，各34例。对照组采用聚乙二醇干扰素α序贯治疗，观察组在对照组基础上联合核苷类药物治疗，比较两组临床治疗总有效率、HBV－DNA转阴率、HBeAg转阴率、HBsAg清除率、肝功能指标变化以及临床不良反应发生情况。结果 观察组临床治疗总有效率为94.11%，高于对照组的82.35%，差异有统计学意义（P＜0.05）；观察组HBV－DNA转阴率、HBeAg转阴率、HBsAg清除率均大于对照组，差异有统计学意义（P＜0.05）；两组治疗后ALT、TBIL均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；观察组不良反应发生率为14.70%，与对照组的11.76%比较，差异无统计学意义（P＞0.05）。结论 聚乙二醇干扰素α序贯联合核苷类药物治疗高病毒载量e抗原阳性乙型肝炎效果确切，可提高治疗总有效率，提升HBV－DNA和HBeAg转阴率以及HBsAg清除率，改善肝功能，且不会增加不良反应。
Abstract:
Objective To study the clinical efficacy of peginterferon α sequential combined with nucleoside drugs in the treatment of high viral load e antigen positive hepatitis B.Methods Totally 68 patients with high viral load e antigen positive hepatitis B were selected from August 2019 to April 2020, and were divided into control group and observation group by random number table method, with 34 cases in each. The control group was treated with polyethylene glycol sequential therapy, and the observation group was treated with nucleoside drugs on the basis of the control group, the total effective rate, negative rate of HBV-DNA, negative rate of HBeAg, clearance rate of HBsAg, changes of liver function index and clinical adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 94.11%, which was higher than that 82.35% of the control group, and the difference was statistically significant(P<0.05); the negative rate of HBV-DNA, the negative rate of HBeAg and the clearance rate of HBsAg in the observation group were higher than those in the control group, and the difference was statistically significant(P<0.05); after treatment, ALT and TBIL in the two groups were lower than before treatment, and the observation group was lower than the control group, and the difference was statistically significant(P<0.05); the incidence of adverse reaction in the observation group was 14.70%, which was comared with 11.76% of the control group, the difference was not statistically significant (P>0.05).Conclusion Peginterferon α sequential combined with nucleoside drugs in the treatment of high viral load e antigen positive hepatitis B is effective, which can improve the total effective rate of treatment, enhance HBV-DNA and HBeAg negative conversion rate and HBsAg clearance rate, and improve liver function, and will not increase the adverse reaction.

参考文献/References:

[1]朱丽,王丽,曾义岚,等.聚乙二醇干扰素α－2a联合恩替卡韦治疗高病毒载量HBeAg 阳性慢性乙型肝炎的临床研究[J].实用药物与临床,2016,19(1):110-113.[2]安丽娜,吴玮,孙晓慧,等.聚乙二醇干扰素α-2a并恩替卡韦治疗HBeAg阳性慢性乙型肝炎的效果[J].齐鲁医学杂志,2016,31(3):366-368.[3]陈璐,郭斯敏,庄焱,等.联合聚乙二醇干扰素-α对恩替卡韦经治HBeAg 阳性慢性乙型肝炎患者的疗效和预测因素[J].肝脏,2015,2(6):434-437.[4]中华医学会肝病学分会,感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志,2015,12(31):1941-1960．[5]Zhang K,Cao H,Liang J,et al.CONSOＲT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients:A prospective,randomized study[J].Medicine,2016,95(31):e4471[6]黄金.聚乙二醇干扰素α 序贯联合核苷类药物治疗高病毒载量e抗原阳性乙型肝炎1年疗效观察[D].杭州:浙江中医药大学,2016.[7]安红杰,何文艳,徐金凤,等.聚乙二醇干扰素α-2a联合阿德福韦治疗e抗原阳性高病毒载量慢性乙型肝炎给药时机的选择[J].解放军医药杂志,2015(8):79-82.[8]曹振环,柳雅立,马丽娜,等.聚乙二醇干扰素α-2a联合拉米夫定或阿德福韦治疗乙型肝炎e抗原阳性慢性乙型肝炎96周疗效观察[J].中华传染病杂志,2016,34(7):422-424.[9]鲍旭丽,渠亚超,熊芳,等.聚乙二醇干扰素联合核苷(酸)类似物96周延长疗程治疗e 抗原阳性慢性乙型肝炎患者的效果观察[J].中国综合临床,2016,32(8):673-676.[10]Wu D,Ning Q.Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome[J].J Infect Dis,2017,216(suppl 8):S771-S777．[11]李仕雄,朱宇佳,许超宇,等.聚乙二醇干扰素α-2a 联合恩替卡韦治疗高病毒载量慢性乙型肝炎疗效观察[J].广西医学,2015,44(5):701-702.[12]贾云利.替比夫定与干扰素α治疗HBeAg 阳性慢性乙型肝炎患者临床疗效观察[J].临床医学研究与实践,2016,1(3):19.[13]Huang J,Zhang K,Chen W,et al.Switching to PegIFNalpha-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs[J].Sci Rep,2017,7(1):13383．[14]许俊,黄敏.拉米夫定联合聚乙二醇干扰素初始和再治疗慢性乙型肝炎合并脂肪肝疗效观察[J]. 实用肝脏病杂志,2016,19(2):210-211.[15]李国军,喻一奇,范平,等.乙型肝炎表面抗原水平对核苷(酸)类似物序贯联合聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者的疗效预测[J].中华传染病杂志,2015,32(2):100-106.

更新日期/Last Update: 1900-01-01